BCWM
ICCM icon

Bartlett & Co Wealth Management’s IceCure Medical ICCM Stock Holding History

Bartlett & Co Wealth Management’s Portfolio ICCM Stock Details ICCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39 Hold
8
– – ﹤0.01% 1325
2026
Q1 		$73 Hold
8
– – ﹤0.01% 1269
2025
Q4 		$153 Hold
8
– – ﹤0.01% 1206
2025
Q3 		$254 Hold
8
– – ﹤0.01% 1155
2025
Q2 		$249 Hold
8
– – ﹤0.01% 1188
2025
Q1 		$294 Hold
8
– – ﹤0.01% 1154
2024
Q4 		$275 Hold
8
– – ﹤0.01% 1095
2024
Q3 		$153 Hold
8
– – ﹤0.01% 1110
2024
Q2 		$185 Hold
8
– – ﹤0.01% 1113
2024
Q1 		$300 Buy
+8
New +$312 ﹤0.01% 1096
2023
Q3 		– Sell
-8
Closed -$277 – 1191
2023
Q2 		$277 Hold
8
– – ﹤0.01% 1128
2023
Q1 		$287 Hold
8
– – ﹤0.01% 1044
2022
Q4 		$380 Hold
8
– – ﹤0.01% 1073
2022
Q3 		$309 Hold
8
– – ﹤0.01% 1157
2022
Q2 		$427 Hold
8
– – ﹤0.01% 1274
2022
Q1 		$607 Buy
+8
New +$620 ﹤0.01% 1039

Other funds holding ICCM

SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Bartlett & Co Wealth Management's ICCM Position: Q2 2026 in Review

Bartlett & Co Wealth Management held its IceCure Medical (ICCM) position steady in Q2 2026 at 8 shares worth $39. The position accounts for ﹤0.01% of the portfolio, ranked #1325.

Bartlett & Co Wealth Management first reported a position in ICCM in Q1 2022 and has held it in 16 quarters since. The position peaked at $607 in Q1 2022. 3 funds tracked by Wall St. Rank hold ICCM as of Q2 2026.

  • Bartlett & Co Wealth Management held 8 shares of IceCure Medical worth $39 as of Q2 2026.
  • Bartlett & Co Wealth Management left its IceCure Medical share count unchanged in Q2 2026.
  • IceCure Medical made up ﹤0.01% of Bartlett & Co Wealth Management's portfolio in Q2 2026, its #1325 holding.
  • Bartlett & Co Wealth Management first reported a position in IceCure Medical in Q1 2022 and has held it in 16 quarters since.
  • Bartlett & Co Wealth Management's IceCure Medical position peaked at $607 in Q1 2022.
  • 3 funds tracked by Wall St. Rank held IceCure Medical as of Q2 2026.

Based on Bartlett & Co Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.